Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Generic Injectables Market 2017-2022 & Feasibility Analysis for Setting up a Generic Injectables Manufacturing Plant - Research and Markets

Research and Markets
Posted on: 28 Aug 17

The "Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report has been added to Research and Markets' offering.

The global generic injectables market reached a value of more than US$ 43 Billion in 2016, exhibiting a CAGR of around 9% during 2009-2016.

Unlike branded drug manufacturers who spend millions of dollars on R&D and marketing, generic drug manufacturers do not require such investments. Moreover, the number of competitors in the generic injectables market is lower as compared to oral generics, resulting in limited price erosion and significantly higher profit margins.

Owing to the advantages offered by generic injectables, governments in various countries are supporting their manufacture. Additionally, an increase in drug shortages, especially in the US, along with patent expiry of a number of blockbuster drugs, aging population and rising prevalence of chronic as well as lifestyle diseases represent some of the other factors driving the growth of the market. According to

The report also provides a comprehensive analysis for setting up a generic injectables manufacturing plant. The study analyses the processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global generic injectables industry in any manner.

The report has also analysed the competitive landscape of the market with some of the key players being Hospira (Pfizer), Fresenius Kabi, Hikma, Sandoz (Novartis), Sagent, Sanofi and Baxter.

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Generic Drug Market

5.1 Market Overview

5.2 Market Performance

5.3 Market Breakup by Region

5.4 Market Forecast

5.5 Major Players

6 Global Generic Drug Delivery Market

6.1 Oral

6.2 Injectables

6.3 Dermal/Topical

6.4 Inhalers

7 Global Generic Injectables Market

7.1 Market Overview

7.2 Market Performance

7.3 Market Breakup by Region

7.4 Market Breakup by Therapeutic Area

7.5 Market Breakup by Distribution Channel

7.6 Market Forecast

8 Global Generic Injectables Market: Performance of Key Regions

9 Market by Therapeutic Area

9.1 Oncology

9.2 Anaesthesia

9.3 Anti-infectives

9.4 Parenteral Nutrition

9.5 Cardiovascular

10 Market by Distribution Channel

10.1 Hospitals

10.2 Retail Pharmacy Stores

11 Global Generic Injectable Market: Competitive Landscape

11.1 Competitive Structure

11.2 Market Breakup by Key Players

12 Generic Injectable Manufacturing Process

12.1 Product Overview

12.2 Detailed Process Flow (Injectable)

12.3 Various Types of Unit Operations Involved

12.4 Mass Balance and Raw Material Requirements

13 Project Details, Requirements and Costs Involved

13.1 Land Requirements and Expenditures

13.2 Construction Requirements and Expenditures

13.3 Plant Machinery

13.4 Machinery Pictures

13.5 Raw Material Requirements and Expenditures

13.6 Packaging Requirements and Expenditures

13.7 Transportation Requirements and Expenditures

13.8 Utility Requirements and Expenditures

13.9 Manpower Requirements and Expenditures

13.10 Other Capital Investments

14 Loans and Financial Assistance

15 Project Economics

15.1 Capital Cost of the Project

15.2 Techno-Economic Parameters

15.3 Product Pricing and Margins Across Various Levels of the Supply Chain

15.4 Taxation and Depreciation

15.5 Income Projections

15.6 Expenditure Projections

15.7 Financial Analysis

15.8 Profit Analysis

16 Key Player Profiles

16.1 Hospira (Pfizer)

16.2 Fresenius Kabi

16.3 Hikma

16.4 Sandoz (Novartis)

16.5 Sagent

16.6 Sanofi

16.7 Baxter

For more information about this report visit

View source version on

Business Wire

Last updated on: 28/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.